Taken together with the fact that JAM-A may also regulate HER2 stability at post-translational levels (both proteasomal [3] and lysosomal [15]), this supports the utility of JAM-A as an excellent potential cancer drug target. The gene discussed is ERBB2; the disease is cancer.